Organon & Co.OGN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · organon.com
Organon & Co. is a global healthcare company spun off from Merck & Co. in 2021, focused on improving the health of women throughout their lives. The company markets a portfolio of over 70 products across women's health (contraception, fertility), biosimilars, and established brands in cardiovascular and other therapeutic areas, reaching more than 140 markets worldwide. Headquartered in Jersey City, New Jersey.
Key ratios
Operating cash flow growth
-10.8%TTM
2025
-25.5%2024
17.5%2023
-6.9%
EPS growth
-70.5%TTM
2025
-78.4%2024
-16.5%2023
11.1%
FCF / Sales
9.3%TTM
2025
8.7%2024
11.9%2023
8.7%
Net margin
3.4%TTM
2025
3.0%2024
13.5%2023
16.3%
ROA
5.7%TTM
2025
6.2%2024
7.4%2023
7.2%
ROE
30.6%TTM
2025
30.6%2024
429.9%
Revenue growth
-2.5%TTM
2025
-2.9%2024
2.2%2023
1.4%
Recent news
Organon Canada Announces the Appointment of Dominic Bégin as President and Managing Director
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Sun Pharma signs Definitive Agreement to Acquire Organon
Track OGN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer